Loading
Loading
GHRH Analogue · DAC (long-acting) and No-DAC (pulsatile) variants
GHRH analogue that binds pituitary GHRH receptors to stimulate pulsatile GH release. The DAC version incorporates a drug-affinity complex that binds serum albumin, dramatically extending half-life. Synergistic with GHRPs for maximal GH secretion.
CJC-1295 is a synthetic peptide analog that has been investigated in preclinical research for its potential role in modulating growth hormone (GH) signaling and endocrine system activity. Structurally designed to mimic growth hormone–releasing hormone (GHRH), CJC-1295 has been studied for its ability to interact with GHRH receptors and influence pulsatile GH release under controlled laboratory conditions. Unlike naturally occurring peptides, it is engineered with modifications intended to extend its stability and duration of action in experimental models.
Across in vitro and animal-based studies, CJC-1295 has been examined for its potential effects on the hypothalamic-pituitary axis, particularly in relation to GH and insulin-like growth factor 1 (IGF-1) signaling pathways. Researchers have explored how the peptide may contribute to sustained endocrine responses, receptor binding dynamics, and downstream cellular signaling processes. These investigations often focus on how prolonged GH activity may influence metabolic regulation, protein synthesis pathways, and tissue-level responses in experimental environments.
In addition to its endocrine-related activity, CJC-1295 has been evaluated for its potential involvement in broader physiological processes linked to hormonal balance and homeostasis. Preclinical studies have explored its interaction with feedback mechanisms that regulate hormone secretion, as well as its potential impact on circadian-associated hormone rhythms and metabolic signaling networks.
To support consistent research outcomes, CJC-1295 has been developed in stabilized forms, including variants designed to bind to plasma proteins and extend half-life in experimental systems. This allows researchers to observe prolonged activity and more consistent signaling effects over time. All findings referenced are derived exclusively from non-clinical studies. There are no established conclusions regarding human safety, pharmacokinetics, dosing, or therapeutic applications, and all observations remain within the scope of ongoing scientific investigation.
Sold strictly as a research chemical for non-human, in-vitro, and laboratory use
FDA approved compound
Listed as prohibited under WADA anti-doping regulations
Prescription availability in Australia and internationally
In Australia, cjc-1295 peptide has no TGA approval for therapeutic use. It is sold by Capital Peptides strictly as a research chemical for non-human, in-vitro, and laboratory research use only.
CJC-1295 Peptide research is most relevant to protocols examining:
GH deficiency and age-related GH decline research
Body composition, muscle and fat ratio studies
Anti-ageing protocols investigating GH restoration
Researchers comparing pulsatile (No DAC) versus continuous (DAC) GH release patterns
Sleep quality and recovery investigations on the GH axis
Initial phase
Compound begins accumulating in target tissue. Most researchers note subtle changes by end of week one. Baseline measurements recommended.
Early response
Measurable effects begin to establish. Mid-cycle assessment is appropriate at this point in well-designed protocols.
Peak activity window
Primary outcomes are typically strongest in this window. Human trial literature provides benchmarks for comparison.
Washout & review
Allow full washout (~5× half-life: No DAC: ~30 min; with DAC: ~8 days). Review data, confirm baseline recovery before any repeat protocol.
GHRH analogue that binds pituitary GHRH receptors to stimulate pulsatile GH release. The DAC version incorporates a drug-affinity complex that binds serum albumin, dramatically extending half-life. Synergistic with GHRPs for maximal GH secretion.
| Parameter | Value |
|---|---|
| Dose range | CJC-1295 No DAC: 100–200 mcg/dose |
| Alt. dose 2 | CJC-1295 DAC: 1–2 mg/week |
| Schedule | No DAC: nightly; DAC: once or twice weekly |
| Route | Subcutaneous |
| Half-life | No DAC: ~30 min; with DAC: ~8 days |
Confusing CJC-1295 with DAC vs No DAC
Fix: they have dramatically different half-lives and dosing frequencies (weekly vs nightly)
Dosing at inconsistent times
Fix: nighttime administration aligns with the natural GH pulse and yields better results
Not pairing with a GHRP (Ipamorelin)
Fix: maximal GH release requires both GHRH and GHRP input
Pushing dose too high continuously
Fix: desensitisation occurs; cycle 8–12 weeks on, 4 weeks off
Community & Anecdotal Signal
Community signal mirrors Ipamorelin closely because the compounds are so frequently used together. CJC-1295 with DAC (Drug Affinity Complex) vs without is a meaningful split in community discussion with DAC is preferred for less frequent dosing; without is preferred by users who want more controlled GH pulses. The CJC/Ipa stack is one of the few peptide combinations where the community has broadly converged on a preferred protocol, suggesting enough accumulated experience to produce signal. Recovery, sleep, and gradual body composition shifts over 12+ weeks are the consistent anecdotal themes.
Anecdotal reports are not clinical evidence. Signal may reflect sourcing quality, dosing variation, and expectation bias.
Available from Capital Peptides
References
For research use only. Capital Peptides products are not approved by the TGA for therapeutic use. By purchasing you confirm you are a licensed research entity or qualified professional.
